Form 4: Director Vicki Sato Sells 22,000 Vir Biotechnology Shares

Director Vicki Sato sold 22,000 shares of Vir Biotechnology, Inc. common stock on April 1, 2026, via a 10b5-1 plan.

Summary

• Director Vicki Sato disposed of 22,000 shares of Vir Biotechnology common stock.
• The shares were sold at a weighted average price of $9.0735 per share.
• The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on March 27, 2025.
• Following the sale, the reporting person retains beneficial ownership of 1,100,391 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and represents a small fraction of the director's total holdings.

Positives

• The transaction was conducted under a pre-planned Rule 10b5-1 trading plan, which typically indicates the sale was not based on non-public information.

Negatives

• The sale represents a reduction in the equity stake held by a member of the Board of Directors.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management sentiment regarding future stock performance.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard corporate governance practice for executives and directors to diversify holdings while avoiding potential conflicts with insider trading regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings in publicly traded biotechnology companies.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the director's total ownership.

Key Dates

Keywords

Vir Biotechnology, VIR, Insider Trading, Form 4, Vicki Sato, Biotech